Vista Pharmaceuticals Ltd (VISTAPH) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Vista Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Resignation of Company Secretary & Compliance Officer
Change in Management · 12 Sept 2026, 4:15 pm
Vista Pharmaceuticals Announces Resignation of Company Secretary and Compliance Officer Vista Pharmaceuticals Limited disclosed the resignation of Mrs. Barkha Jain from her role as Company Secretary and Compliance Officer (Key Managerial Personnel), effective from the close of business hours on 4th Sep'26. According to the regulatory filing under SEBI LODR Regulations, the resignation was tendered to pursue external career opportunities outside the organization. The company's Board of Directors has formally noted her communication and placed on record appreciation for her contributions during her tenure.
Results for the quarter ended 30.06.2026
Outcome · 14 Aug 2026, 9:06 pm
Vista Pharmaceuticals: Zero Revenue, Growing Losses, and Going Concern Risk in Q1FY27 Vista Pharmaceuticals reported zero revenue from operations for Q1FY27 ended 30 Jun'26, down from ₹151.88 lakhs YoY. The net loss narrowed slightly to ₹98.59 lakhs from ₹129.04 lakhs YoY, while the loss before tax was ₹132.71 lakhs. Significant financial stress is evident, with credit facilities classified as NPAs, negative working capital, and current liabilities exceeding current assets by ₹183.32 lakhs. These factors raise material uncertainty about its ability to continue as a going concern, despite management preparing results on that basis.
Results for the quarter ended 30.06.2026
Financial Result · 14 Aug 2026, 9:00 pm
Vista Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakhs) ■ Revenue: 0.0 (-100.0% YoY) ■ EBITDA: -84.3 (+24.1% YoY | +88.1% QoQ) ■ EBITDA Margin (%): 0.0 (Loss to Profit YoY) ■ PAT: -98.6 (+23.6% YoY | +83.2% QoQ) ■ EPS (INR): -0.16 (+27.3% YoY | +83.2% QoQ)
Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve 1. Unaudited financial ....
Intimation · 14 Aug 2026, 5:30 am
Vista Pharma Board to Approve Q1 FY27 Results on 14 Aug '26 Vista Pharmaceuticals Ltd (BSE: 524711) has scheduled a Board of Directors meeting for 14 Aug '26. The key agenda item is the consideration and approval of the unaudited financial results for the first quarter ended 30 Jun '26. The board will also review the limited review report for the same period. This meeting will be crucial for assessing the company's performance at the start of the fiscal year.
Board meeting outcome
Financial Result · 29 May 2026, 8:46 pm
Vista Pharmaceuticals Ltd - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakh) ■ Revenue: 0.0 (-100.0% YoY | -100.0% QoQ) ■ EBITDA: -706 (-674.5% YoY | -134.9% QoQ) ■ EBITDA Margin (%): 0.0 (Loss to Profit YoY | Loss to Profit QoQ) ■ PAT: -586 (-292.0% YoY | -152.8% QoQ) ■ EPS (INR): -0.91 (-15.2% YoY | -133.3% QoQ)
Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve 1. Audited financial ....
Intimation · 29 May 2026, 5:30 am
Vista Pharmaceuticals to Consider Q4 & FY26 Results on 29-May-26 Vista Pharmaceuticals (BSE: 524711) has scheduled a Board of Directors meeting for Fri, 29th May'26. The agenda includes the consideration and approval of the audited financial results and the audit report for the quarter and financial year ended 31st Mar'26.
<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> ....
Others (Uncategorized) · 29 Apr 2026, 5:30 pm
Vista Pharma Not Classified as a Large Corporate, Exempt From Debt Fundraising Rules Vista Pharmaceuticals Ltd (BSE: 524711) announced on 29 Apr'26 that it does not fall under the Large Corporate (LC) category as per SEBI's framework. Consequently, the company is not subject to the mandatory requirement of raising a portion of its incremental borrowings through the issuance of debt securities. The disclosure for FY26 confirms no mandatory borrowing was required and no actual borrowing was done via debt securities, indicating no shortfall or applicable penalties for the reported period.
Un audited Financial Results for the quarter ended 31.12.2025
Outcome · 13 Feb 2026, 8:56 pm
Vista Pharma Q3FY26: Revenue Declines and Net Loss Widens Vista Pharmaceuticals reported a widened Net Loss of Rs 231.94 lakhs for the quarter ended 31 Dec'25, compared to a loss of Rs 132.23 lakhs YoY. Revenue from operations declined 5.4% YoY to Rs 241.82 lakhs. The loss before tax increased to Rs 328.04 lakhs from Rs 180.44 lakhs YoY, impacted by higher expenses. Notably, the company recognized an Expected Credit Loss provision of Rs 205.43 lakhs against long-pending trade receivables. Basic EPS for the quarter stood at Rs (0.41).
Results for the quarter ended 31.12.2025
Financial Result · 13 Feb 2026, 8:53 pm
Vista Pharmaceuticals Reports Widened Q3FY26 Loss on Higher Expenses Vista Pharmaceuticals reported a widened net loss of ₹231.94 lakh for Q3FY26 ended 31 Dec'25, compared to a loss of ₹132.23 lakh YoY. Revenue from operations declined 5.4% YoY to ₹241.82 lakh. The loss before tax increased to ₹328.04 lakh from ₹180.44 lakh YoY, driven by higher material and other expenses. The company also recognized an Expected Credit Loss provision of ₹205.43 lakh against trade receivables. Basic EPS for the quarter stood at ₹(0.41), deteriorating from ₹(0.07) in the prior-year period.
Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/02/2026 ,inter alia, to consider and approve 1. Unaudited financial ....
Intimation · 23 Feb 2026, 5:30 am
Vista Pharma Schedules Board Meeting for Q3 Results Vista Pharmaceuticals Ltd (BSE: 524711) will hold a Board of Directors meeting on 13 Feb'26. The agenda includes the consideration and approval of the unaudited financial results and the Limited Review Report for the quarter and nine months ended 31 Dec'25. This event is a key catalyst for the stock, pending the release of its Q3 performance data.
Disclosure
Others (Uncategorized) · 03 Feb 2026, 8:39 pm
Vista Pharmaceuticals Forms Joint Venture with Pleiades Therapeutics Vista Pharmaceuticals has entered into a joint venture with Pleiades Therapeutics, announced on 03 Feb'26. The partnership will pursue end-to-end development of generic and specialty pharmaceutical products for regulated and Rest-of-World (ROW) markets. This strategic move aims to combine Pleiades' R&D expertise with Vista's manufacturing and established marketing presence in the United States and other key markets. The collaboration is expected to enhance operational capabilities, expand market reach, and strengthen the competitive positioning of both companies globally.
Un audited financial Results for the quarter and half year ended 30.09.2025
Outcome · 13 Nov 2025, 9:26 pm
Un audited Financials Results for the quarter and half year ended 30.09.2025
Financial Result · 13 Nov 2025, 9:24 pm
Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 ,inter alia, to consider and approve 1. Unaudited financial ....
Intimation · 13 Nov 2025, 5:30 am
Scrutinizer''s report and Outcome of AGM
Annual General Meeting · 30 Sept 2025, 11:15 pm
Outcome of AGM of Vista Pharmaceutical Limited held on 30.09.2025
Annual General Meeting · 30 Sept 2025, 11:12 pm
Intimation of Book Closure regrading 34th Annual General Meeting of the company
Annual General Meeting · 08 Sept 2025, 9:48 pm
Submission of Annual Report for the FY 2024-25
Others (Uncategorized) · 08 Sept 2025, 9:46 pm
Notice of 34th Annual General Meeting of Vista Pharmaceuticals Limited to be held on Tuesday 30th September 2025
Annual General Meeting · 08 Sept 2025, 9:32 pm
Re appointment of Mr. Murali Meraga (DIN:05237507) as an Managing Director of the company
Others (Uncategorized) · 14 Aug 2025, 12:01 am
Re Appointment of Mr. Pavan Sathvik Gilaka (DIN: 09733182) as An Whole time Director of the company
Others (Uncategorized) · 13 Aug 2025, 11:58 pm
Re-appointment of Mr. Dhananjaya Alli (DIN: 00610909) as an Whole Time Director of company
Others (Uncategorized) · 13 Aug 2025, 11:55 pm
Outcome of the Board Meeting - Unaudited Financial results for quarter ended 30.06.2025
Outcome · 13 Aug 2025, 10:16 pm
Unaudited Financial results for the quarter ended 30.06.2025
Financial Result · 13 Aug 2025, 10:12 pm
Vista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2025 ,inter alia, to consider and approve 1. Unaudited Financial ....
Intimation · 13 Aug 2025, 5:30 am